SUIT-016: Difference between revisions
From Bioblast
No edit summary |
Beno Marija (talk | contribs) No edit summary |
||
Line 84: | Line 84: | ||
| [[S]] | | [[S]] | ||
| CII | | CII | ||
| The complete | | The complete ET capacity in state S may not be obtained after oligomycin. If apparent P/E>1.0, this is corrected to 1.0. | ||
|- | |- | ||
Line 91: | Line 91: | ||
| [[S]] | | [[S]] | ||
| CII | | CII | ||
| If [[cytochrome c control factor]]s = 0.0, the cytochrome ''c'' test conducted at this very late | | If [[cytochrome c control factor]]s = 0.0, the cytochrome ''c'' test conducted at this very late ET-pathway state provides an additional indication of stability of the mt-preparation during the experimental assay. Application of the cytochrome ''c'' test earlier in the protocol ([[1GM;2D;3S;4U;5Rot-]]: 1GM;2D;2c;3S; ..) is preferable, ifΒ [[cytochrome c control factor]]s > 0.0 may be observed occasionally or regulary. If such cytochrome ''c'' effects are not exclusion criteria, then OXPHOS states with all substrate combinations can beΒ compared in the presence of cytochrome ''c''. | ||
|- | |- |
Revision as of 13:44, 20 October 2017
Description
Abbreviation: FNS(GM)
Reference: A Gnaiger 2015 Scand J Med Sci Sports
MitoPedia concepts:
SUIT protocol,
SUIT A
- SUIT-category: FNS(GM)
- SUIT protocol pattern: diametral
References
Year | Reference | Organism | Tissue;cell | |
---|---|---|---|---|
Gnaiger 2015 Scand J Med Sci Sports | 2015 | Gnaiger E, Boushel R, SΓΈndergaard H, Munch-Andersen T, Damsgaard R, Hagen C, DΓez-SΓ‘nchez C, Ara I, Wright-Paradis C, Schrauwen P, Hesselink M, Calbet JAL, Christiansen M, Helge JW, Saltin B (2015) Mitochondrial coupling and capacity of oxidative phosphorylation in skeletal muscle of Inuit and caucasians in the arctic winter. https://doi.org/10.1111/sms.12612 | Human | Skeletal muscle |
1OctM;2D;3G;4S;5Rot;6Omy;7U;7c-
1OctM;2D;3G;4S;5Rot;6Omy;7U;7c;8Ama
Step | Respiratory state | Pathway control | Pathway to Q | Comment |
---|---|---|---|---|
1OctM | OctM(L) | F | CETF | |
2D | OctM(P) | F | CETF | OXPHOS coupling efficiency in state F. |
3G | GMOct(P) | FN | FAO&CI | F/N ratio or (N-F)/N flux control factor of OXPHOS capacity. |
4S | GMSOct(P) | FNS | FAO&CI&II | Additive effect of the NS pathway combination, compared to the sum of N+S pathway fluxes measured separately, in the OXPHOS state and the presence of F. |
5Rot | S(P) | S | CII | The P/E ratio is not obtained in the FNS state, with preference given to the next steps for OXPHOS coupling efficiency. A succinate concentration of >10 mM may be required for saturating SP capacity. |
6Omy | S(L) | S | CII | OXPHOS coupling efficiency in state S, comparable to state F. |
7U | S(E) | S | CII | The complete ET capacity in state S may not be obtained after oligomycin. If apparent P/E>1.0, this is corrected to 1.0. |
7c | S(E) | S | CII | If cytochrome c control factors = 0.0, the cytochrome c test conducted at this very late ET-pathway state provides an additional indication of stability of the mt-preparation during the experimental assay. Application of the cytochrome c test earlier in the protocol (1GM;2D;3S;4U;5Rot-: 1GM;2D;2c;3S; ..) is preferable, if cytochrome c control factors > 0.0 may be observed occasionally or regulary. If such cytochrome c effects are not exclusion criteria, then OXPHOS states with all substrate combinations can be compared in the presence of cytochrome c. |
8Ama | ROX | ROX | ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the basis of ROX correction of mitochondrial respiration (mt). |